Neogen Corporation
NEOG
NASDAQ·Healthcare·Medical - Devices·Mkt cap $2.6B
$11.83
▲ +1.63%
P/E
-356.33
Mkt Cap
$2.6B
52-Wk Range
$4.90–$12.85
52-Week Range
$4.90 - $12.85
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 109.0% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
5 reasons
- Comprehensive product portfolio addressing multiple food and animal safety concerns
- Established relationships with major food processors, producers, and veterinary professionals globally
- Proprietary diagnostic technologies and rapid testing capabilities (AccuPoint Advanced)
- Regulatory expertise and compliance certifications across international markets
- Integrated business model serving interconnected food safety and animal health ecosystems
Bear Case
2 risks
- Above-average volatility (beta 1.8).
- Premium valuation to Life Sciences Tools peers
Growth
Turning profitable
Increasing regulatory requirements and food safety standards worldwide
Value
Premium valuation to Life Sciences Tools peers
Momentum
Hot
+30.4% over 3m
Quality
Strong
Excellent business quality
Dividend
None
No dividend
Smart-money signal
Who's buying NEOG right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Oct 8, 2026
JUL 30, 2026
Reported EPS of $0.09 vs $0.06 consensus (+58.8% surprise). Revenue of $225.3M vs $212.3M expected (+6.1%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+58.8%
Revenue trend · last 8Q
—
—
-3%
-5%
-4%
-3%
-4%
-0%
Q1 24
Q2 24
Q3 25
Q4 25
Q1 25
Q2 25
Q3 26
Q4 26
$217.0M
$231.3M
$221.0M
$225.5M
$209.2M
$224.7M
$211.2M
$225.3M
Margins · last 8Q
Gross
47.9%
Operating
1.4%
Profit
-5.0%
Wall Street consensus
1 analyst · 0% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
0%
Hold
100%
Sell
0%
Median Price Target
—
Latest: Piper Sandler · Aug 3, 2026
vs Industry
How NEOG stacks vs Medical - Devices
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related